Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Li

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal for Immunotherapy of Cancer|June 16, 2021
Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expressionRichard S P Huang, Brennan Decker, Karthikeyan Murugesan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2025
LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized TrialAndrew J Armstrong, Hilary Dietz, David Balli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2022
Quantifying the Value of Multigene Testing in Resected Early Stage Lung AdenocarcinomaBharathi Muthusamy, Kira Raskina, Katherine T Lofgren, et al.
JTO Clinical and Research Reports|September 12, 2022
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLCLee S Schwartzberg, Gerald Li, Khaled Tolba, et al.
JAMA Network Open|October 29, 2020
Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid TumorsChangxia Shao, Gerald Li, Lingkang Huang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 2, 2025
Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancerBrian M Slomovitz, Natalie Danziger, Julia C F Quintanilha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2025
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate CancerChadi Hage Chehade, Ryon P Graf, Zeynep Irem Ozay, et al.
JCO Precision Oncology|June 7, 2024
Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic MelanomaMiles C Andrews, Gerald Li, Ryon P Graf, et al.
The Oncologist|February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCPhilip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
Journal for Immunotherapy of Cancer|January 17, 2023
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysisRichard S P Huang, David P Carbone, Gerald Li, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|June 16, 2021
Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expressionRichard S P Huang, Brennan Decker, Karthikeyan Murugesan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2025
LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized TrialAndrew J Armstrong, Hilary Dietz, David Balli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2022
Quantifying the Value of Multigene Testing in Resected Early Stage Lung AdenocarcinomaBharathi Muthusamy, Kira Raskina, Katherine T Lofgren, et al.
JTO Clinical and Research Reports|September 12, 2022
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLCLee S Schwartzberg, Gerald Li, Khaled Tolba, et al.
JAMA Network Open|October 29, 2020
Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid TumorsChangxia Shao, Gerald Li, Lingkang Huang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 2, 2025
Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancerBrian M Slomovitz, Natalie Danziger, Julia C F Quintanilha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2025
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate CancerChadi Hage Chehade, Ryon P Graf, Zeynep Irem Ozay, et al.
JCO Precision Oncology|June 7, 2024
Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic MelanomaMiles C Andrews, Gerald Li, Ryon P Graf, et al.
The Oncologist|February 24, 2024
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCPhilip C Mack, Rachel B Keller-Evans, Gerald Li, et al.
Journal for Immunotherapy of Cancer|January 17, 2023
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysisRichard S P Huang, David P Carbone, Gerald Li, et al.
Pageof 4